AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01440855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facing Forward booklet
Description: NCI's (NCI: National Cancer Institute) Facing Forward 61-page booklet, which describes common feelings and reactions that cancer survivors experience during the re-entry phase and offers behavioral recommendations to help them through this period, i.e., ways of dealing with common problems and guidelines for managing physical, social, and emotional health. Booklet sections: Congratulations on Finishing Your Cancer Treatment, Getting Follow-up Medical Care, Ways to Manage Physical Changes, Body Changes and Intimacy, Your Feelings, Social and Work Relationships, Reflection, 6-page Appendix, which provides information on Financial and Legal Matters, and Resource Organizations.
Study NCT01302353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emulsified Isoflurane
Study NCT03083457 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-tidal volume ventilation
Description: Volume-control ventilation with tidal volume=7 ml/kg of predicted body weight for the entire surgical procedure. Respiratory rate will be set to maintain EtCO2 within a physiological range and kept unchanged for the entire duration of the study
Study NCT03083457 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scheduled recruiting maneuvers
Description: Pressure-control ventilation inspiratory pressure=10 cmH2O. Steplike 5-cmH2O-PEEP increase every 30 seconds to achieve a peep of 35 cmH2O, followed by 5-cmH2O-PEEP reduction every 30 seconds to set PEEP
Study NCT03546270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swimming
Description: This group completed 20-weeks of swimming
Study NCT04231799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bathing
Description: Traditionally, it is the process of washing the newborn in the first hours of life to remove blood, meconium, varnish and other infectious substances.
Study NCT05306613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting
Description: After consuming breakfast, participants sat on a chair for 180 min. After 180 min, lunch was provided. After finishing lunch, participants sat on a chair for another 120 min.
Study NCT05306613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breaking sitting
Description: After consuming breakfast, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, lunch was provided. After finishing lunch, participants continued 2 min of walking every 20 min for the following 120 min.
Study NCT03161652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DME lactose pill
Description: Patients with DME will take placebo orally 3 times a day (TID) for 8 weeks.The placebo is taken on top of standard therapy for diabetes and blood pressure control.
Study NCT03161652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DME levosulpiride
Description: Patients with DME will take levosulpiride (75 mg/day) orally TID for 8 weeks. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
Study NCT00251680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and lipid-lowering therapy
Description: Lapaquistat acetate 50 mg, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
Study NCT00251680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipid-lowering therapy
Description: Lapaquistat acetate placebo-matching tablets, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
Study NCT03161652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DR lactose pill
Description: Patients with non-proliferative DR will take a lactose pill (placebo) orally TID for 8 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
Study NCT04518800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jin Youli(PEG-rhG-CSF)
Description: Jin Youli(PEG-rhG-CSF) was given 24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight \<45 kg. Inject once every chemotherapy cycle
Study NCT03161652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR levosulpiride
Description: Patients with non-proliferative DR will take levosulpiride (75 mg/day) orally TIDfor 8 weeks. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
Study NCT01701180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 24 IU; 3 puffs per nostril, each with 4 IU OXT
Study NCT01701180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01383759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
Description: The treatment has three phases:~1) Initial treatment phase: This phase consists of 1-3 21-day-cycles of a combination regimen that includes bortezomib 1.3 mg/m2, IV or Subcutaneous Injection (SQ), on days 1, 4, 8, and 11; and dexamethasone 40 mg PO or IV, on days 1, 4, 8, and 11. Stem cell mobilization and HDM/ASCT. Post-ASCT consolidation/maintenance treatment phase: This phase consists of six cycles of bortezomib 1.3 mg/m2, IV or (SQ) with dexamethasone 20 mg PO or IV administered on days 1, 8, 15, and 22 every 12 weeks +/- 2 weeks. Long Term Follow Up will cease when all patients on study have fulfilled the requirements for at least five follow up appointments.
Study NCT02848859 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Go! to Sleep
Description: This is an online interactive program that delivers cognitive behavioral therapy for insomnia via the internet.
Study NCT02848859 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Sleep Education
Description: Providing patients information on healthy sleep and habits to promote healthy sleep.
Study NCT02848859 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Sleep Education
Description: Providing patients information on healthy sleep and habits to promote healthy sleep.
Study NCT02469558 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Winclove 851 and 110
Description: prebiotic and probiotic mixture
Study NCT02469558 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: white powder without pro/probiotic
Study NCT02201732 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Description: Performed under general or local anesthesia, antibioprophylaxis in accordance to center practices may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
Study NCT02201732 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Curettage
Description: Performed under general or local anesthesia, the used material may be rigid or flexible vacurette. In the same way, the prophylactic antibiotic, the diameter of the used vacurette, the importance of cervical dilation necessary and a possible peroperative ultrasound guidance will be left at the discretion of the operator and habits of the center. A check of the uterine vacuity by foam curette will be conducted at the end of curettage.
Study NCT01079000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opinion Leader letter
Description: The patients' PCP will be notified by fax about the ED visit and management. The Opinion Leader letter will contain a summary of the current asthma guidelines for ambulatory care (including: asthma education, long-term recommendations, smoking cessation, and action plan) signed by a local opinion leader. A review of the patient's management within a week of the ED visit will be recommended. The patient will also receive information regarding their acute exacerbation and will be told to review the current management of their disease with their PCP.
Study NCT01079000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Involvement of a care manager
Description: The involvement of a care manager will encourage patients' to pursue follow-up, provide management review and offer brief education via telephone within a week of being discharged
Study NCT03067025 — intervention group
Intervention type: DEVICE
Intervention: Actigraphy
Description: Actiwatch Spectrum Plus will be worn on the non-dominant wrist 24 hours/day for seven days. Actigraphy is a valid and reliable objective measure of sleep patterns, including sleep quality, duration, and timing when compared to polysomnography (PSG).
Study NCT01079000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care provided to asthma patients when discharged from the ED
Study NCT01079000 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care provided to asthma patients when discharged from the ED
Study NCT04354740 — intervention group
Intervention type: PROCEDURE
Intervention: with percutaneous coronary intervention (PCI) are with new-generation drug-eluting stents (DES)
Description: II-PCI:~-Coronary angiography and intervention will be done according to the European guidelines of ACS revascularization.~III-CABG:
Study NCT03047512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Internet-based program
Description: * Adolescents who obtain a score between 2 and 4 on the PHQ-3 will be invited to use the information module, the psychoeducational material and the symptom monitoring with personalized automatic feedback.~* Adolescents who obtain a score between 5 and 6 on the PHQ-3 will be invited to use, in addition to the above, group forum activities (peer support moderated by mental health professionals) and the possibility of a chat (individualized support by mental health professionals).~* Adolescents who obtain a score greater than 6 on the PHQ-3 or that have suicidal thoughts will be invited to see the mental health counselor of the institution and the possibility of their reference to face-to-face professional attention will be considered.
Study NCT02530086 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube placement
Description: Placement of a Nasogastric tube
Study NCT02530086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Nasogastric tube use
Description: No placement of a Nasogastric tube
Study NCT04518527 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Tape
Description: The tape is an elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability
Study NCT04518527 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tape
Description: The tape is an elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability
Study NCT00005009 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varivax®
Description: Each participant will receive 2 doses of Varivax 6 to 8 weeks apart.
Study NCT02263222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDT-10013
Study NCT01002417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MCS-2 15 mg/day
Description: One MCS-2 15 mg soft-gel capsule plus one matching placebo capsule, oral daily for 12 weeks.
Study NCT01002417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MCS-2 30 mg/day
Description: Two MCS-2 soft-gel capsules, oral daily for 12 weeks.
Study NCT01002417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two matching placebo soft-gel capsules, oral daily for 12 weeks.
Study NCT02423200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-745
Description: Orally-active P38 MAP kinase alpha-selective inhibitor
Study NCT00897507 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02729727 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CryoBalloon Ablation System
Description: Tissue Ablation using CryoBalloon Ablation System
Study NCT01631760 — intervention group
Intervention type: GENETIC
Intervention: no intervention
Description: We will be analyzing MicroRNA in subjects with Asthma Exacerbations by various age groups, Ages 5-12yrs, 13-55yrs, and 56-85yrs for genetic similarities and differences.
Study NCT01834625 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET scan
Study NCT04057729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297
Description: 10mg/capsule.
Study NCT03572686 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ropivacaine 0.5% 20mL
Description: In Group RH, participants received supraclavicular brachial plexus block with ropivacaine 0.5% 20ml at the end of surgery.
Study NCT03572686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine 0.25% 20ml
Description: In Group RL, participants received supraclavicular brachial plexus block with ropivacaine 0.25% 20ml at the end of surgery.
Study NCT03572686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25% 20ml + dexamethasone 8mg
Description: In Group RLD, participants received supraclavicular brachial plexus block with ropivacaine 0.25% 20ml + dexamethasone 8mg at the end of surgery.
Study NCT01214655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2523355
Description: Administered as a 1-hour IV infusion for at least 2 cycles. Cycle length is 21 days. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
Study NCT04282109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Paclitaxel
Description: Combination treatment: Nivolumab 240 mg will be administered via IV infusion every 2 weeks. Paclitaxel 80mg/m2 will be administered via IV infusion weekly. After 12 weeks from the start of the combined treatment paclitaxel will be stopped.~Maintenance treatment with nivolumab 480 mg every 4 weeks will start two weeks after the last administration of nivolumab 240 mg. Once nivolumab is administered at 480 mg, paclitaxel can no longer be administered.~Nivolumab will be continued alone until disease progression, unacceptable toxicity or withdrawal of consent up to a maximum of 24 months.
Study NCT04282109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab + Paclitaxel
Description: Combination treatment: Cetuximab 250 mg/m2 (first dose of 400 mg/m2) administered via IV infusion weekly plus weekly paclitaxel (80 mg/m2) administered via IV infusion.~After 12 weeks from the start of the combined treatment paclitaxel will be stopped and weekly cetuximab will be continued alone until disease progression, unacceptable toxicity or withdrawal of consent up to a maximum of 24 months.
Study NCT00278473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meta-Cognitive Therapy
Description: Cognitive Behavioral Group Treatment
Study NCT01012895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Tablets, Oral, 60 mg, once daily, 24 weeks
Study NCT02690350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1784
Description: Solution for solution in 5% dextrose for infusion, intravenously administered every 2 weeks (q2w) as a 250 mL IV, along with colestyramine or equivalent if clinically indicated
Study NCT01012895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032
Description: Tablets, Oral, 600 mg, twice daily, 24 weeks
Study NCT01012895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032
Description: Tablets, Oral, 200mg, twice daily, 24 weeks
Study NCT01012895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032
Description: Tablets, Oral, 200 mg, once daily, 24 weeks
Study NCT01012895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon alfa-2a
Description: Syringe, Subcutaneous Injection, 180 µg, once weekly
Study NCT01012895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, Oral~For subjects weighing \< 75 kg: 1000 mg; For subjects weighing ≥ 75 kg: 1200 mg~Twice daily (\< 75 kg: 400 mg in ante meridian (AM) and 600 mg in post meridian (PM); ≥ 75 kg: 600 mg in AM and PM), 24 weeks
Study NCT00278473 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Description: Social Support Problem-Solving Group Treatment
Study NCT02224794 — intervention group
Intervention type: DEVICE
Intervention: Ovation® Abdominal Stent Graft Platform
Study NCT04649437 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Quantitative sensory testing
Description: Quantitative sensory testing recordings will be collected by pressure algometry Assessment of temporal summation of pressure pain and conditioning pain modulation will be used to investigate the involvement of pain sensitization.
Study NCT00352664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: 5 mg once a day by mouth for 7 day cycle. After evaluation on Day 8, all participants will be offered donepezil every day for 7 days.
Study NCT00352664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once a day by mouth for one 7 day cycle. After evaluation on day 8, all participants offered donepezil every day for 7 days.
Study NCT04707833 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serological testing for COVID-19 infection
Description: The tests used will be the following:~EUROIMMUN SARS-CoV-2(IgA) ELISA ELISA SARS-CoV-2 (IgG) EUROIMMUN WANTAI SARS-CoV-2 Ab ELISA WANTAI SARS-CoV-2 IgM ELISA Abbott Architect SARS-CoV-2 IgG Diasorin SARS LINK CoV-2 S1/S2 IgG Roche ECL anti-SARS-Cov-2 (combined IgG IgM IgA)
Study NCT03161652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DR vitrectomy lactose pill
Description: Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will have to take a lactose pill (placebo) orally TID for one week. The last placebo pill will be taken on the morning of the day vitrectomy is performed. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
Study NCT03161652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR vitrectomy levosulpiride
Description: Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will take levosulpiride (75 mg/day) orally TID for one week. The last pill will be taken on the morning of the day vitrectomy is performed. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
Study NCT00403611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel 60 mg/kg
Description: Praziquantel (Distocide) 60 mg/kg single oral dose
Study NCT00403611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel 40 mg/kg
Description: Praziquantel (Distocide) 40 mg/kg single oral dose
Study NCT03039686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7239361
Description: Take RO7239361 subcutaneously on specified days over a 48 week blinded period
Study NCT03039686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for RO7239361
Description: Take placebo subcutaneously on specified days over a 48 week blinded period
Study NCT02246244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Study NCT02246244 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01845194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Codeine
Description: Treatment period 2:~5 mg Codeine once
Study NCT01845194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Treatment period 1:~0.2 mg Midazolam 3x~Treatment period 2:~1 mg Midazolam once
Study NCT01845194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Treatment period 2:~5 mg Pravastatin once
Study NCT01845194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torsemide
Description: Treatment period 1:~2.5 mg Torsemide 3x~Treatment period 2:~0.25 mg Torsemide once
Study NCT01845194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talinolol
Description: Treatment period 1:~50 mg Talinolol 3x~Treatment period 2:~2.5 mg Talinolol once
Study NCT01845194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Treatment period 1:~50 mg Caffeine 3x
Study NCT01845194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Treatment period 1:~5 mg Metoprolol 3x
Study NCT02393404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PT-FMT
Description: Physiotherapeutic functional movement-power training
Study NCT02393404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMT alone
Description: Physiotherapeutic power training
Study NCT02894541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 100mg
Study NCT02894541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 200mg
Study NCT01958502 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: surgical treatment of non union with mesenchymal stem cells with BMP2 within a 3-D tissue engineered scaffold